XT
NRIX icon

XTX Topco’s Nurix Therapeutics NRIX Stock Holding History

XTX Topco’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.12M Buy
87,537
+47,151
+117% +$803K 0.03% 1057
2026
Q1 		$626K Buy
40,386
+28,866
+251% +$479K 0.01% 1819
2025
Q4 		$219K Sell
11,520
-11,282
-49% -$162K 0.01% 2333
2025
Q3 		$211K Buy
+22,802
New +$237K 0.01% 1807
2025
Q2 		– Sell
-18,716
Closed -$222K – 2914
2025
Q1 		$222K Buy
+18,716
New +$313K 0.01% 1627
2024
Q3 		– Sell
-15,729
Closed -$328K – 2436
2024
Q2 		$328K Sell
15,729
-10,611
-40% -$165K 0.03% 900
2024
Q1 		$387K Buy
26,340
+14,558
+124% +$157K 0.05% 642
2023
Q4 		$122K Sell
11,782
-10,155
-46% -$69.6K 0.03% 1093
2023
Q3 		$172K Buy
+21,937
New +$200K 0.03% 1065
2023
Q1 		– Sell
-10,795
Closed -$119K – 1540
2022
Q4 		$119K Sell
10,795
-13,084
-55% -$158K 0.03% 971
2022
Q3 		$311K Buy
+23,879
New +$378K 0.08% 477

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

XTX Topco's NRIX Position: Q2 2026 in Review

XTX Topco increased its Nurix Therapeutics (NRIX) stake by 117% in Q2 2026, buying an estimated $803K and bringing the position to 87,537 shares worth $2.12M. The position accounts for 0.03% of the portfolio, ranked #1057.

XTX Topco first reported a position in NRIX in Q3 2022 and has held it in 11 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • XTX Topco held 87,537 shares of Nurix Therapeutics worth $2.12M as of Q2 2026.
  • XTX Topco bought 47,151 Nurix Therapeutics shares in Q2 2026, an estimated $803K.
  • Nurix Therapeutics made up 0.03% of XTX Topco's portfolio in Q2 2026, its #1057 holding.
  • XTX Topco first reported a position in Nurix Therapeutics in Q3 2022 and has held it in 11 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.